Ubiquitin-mediated proteolysis plays a central role in controlling intracellular levels of essential regulatory molecules such as p53, cyclins, myc, BRCA1, HIF-1a, etc. The Kruppel-like factor 5 (KLF5) transcription factor regulates biological processes involved in carcinogenesis, angiogenesis, and smooth muscle cell differentiation. In carcinogenesis, KLF5's role has been indicated by frequent genetic deletion as well as functional studies. Here we show that KLF5 is an unstable protein with a short half-life. Destruction of KLF5 was prevented by each of the proteasome-specific inhibitors tested but not by an inhibitor for trypsin-like proteases and cysteine proteases or by a lysosome inhibitor in epithelial cells. Furthermore, KLF5 underwent ubiquitination, and deletion of a 56-amino-acid sequence adjacent to a known transactivation domain of KLF5 significantly reduced its ubiquitination and degradation. Interestingly, cancer cells appeared to be more active in KLF5 degradation than untransformed epithelial cells, yet their proteasome activity was not higher. These results suggest that KLF5 protein is degraded at least in part through ubiquitinationproteasome pathway, which may have become hyperactive for KLF5 in cancer cells.
Introduction
The Kruppel-like factor 5 (KLF5/IKLF/BTEB2) encodes a zinc-finger transcription factor. It plays an important role in various aspects of carcinogenesis including cell proliferation, differentiation, cell cycle regulation, and angiogenesis (Dang et al., 2000; Black et al., 2001; Sun et al., 2001; Chen et al., 2002 Chen et al., , 2003 Shindo et al., 2002; Bateman et al., 2004; Nandan et al., 2004) . Through interactions with other proteins such as CBP/P300 (Miyamoto et al., 2003) , retinoid acid receptor (Shindo et al., 2002) , and NF-kB (Aizawa et al., 2004) in different cell systems, KLF5 has been shown to induce the expression of different genes including smooth muscle cell differentiation marker SM22a (Adam et al., 2000) , cyclin D1 (Bateman et al., 2004; Nandan et al., 2004) , platelet-derived growth factor a (PDGFa) (Aizawa et al., 2004; Usui et al., 2004) , and possibly transforming growth factor b (TGF-b) (Shindo et al., 2002) .
The function of KLF5 in carcinogenesis appears to be context-dependent. Our recent studies showed that KLF5 undergoes frequent genetic deletion and reduction of expression in human prostate and breast cancers (Chen et al., 2002 (Chen et al., , 2003 , and re-expression of KLF5 in KLF5-deficient cancer cells significantly inhibits colony formation in vitro (Chen et al., 2002 (Chen et al., , 2003 . These studies establish KLF5 as a strong candidate for the tumor suppressor gene located at the q21 band of chromosome 13 (13q21), whose deletion frequently occurs in many types of human tumors (Knuutila et al., 1999) . In fibroblasts, however, overexpression of KLF5 stimulates cell growth, enhances transformation, and likely mediates Ras oncogene's transforming activity (Sun et al., 2001; Nandan et al., 2004) . Therefore, KLF5 appears to have different functions in epithelial cells versus fibroblasts. Consistent with the concept of context-dependent role, a recent study showed a growth-promoting role of KLF5 in nontransformed epithelial cells but a growth inhibitory role in cancer cells (Bateman et al., 2004) .
KLF5 also functions in other physiological and pathological conditions such as embryonic development (Ohnishi et al., 2000) , cardiovascular remolding (Shindo et al., 2002) , wound healing (Ogata et al., 2000) , and cardiac transplantation rejection (Wada et al., 2000 (Wada et al., , 2001 . It has been reported that expression levels of KLF5 change during embryogenesis (Ohnishi et al., 2000) , complete knockout of KLF5 is embryonic lethal in mice (Shindo et al., 2002) , and KLF5 was haploinsufficient in inducing vascular conditions (Shindo et al., 2002) . Recent studies showed that KLF5 is a target of Wnt signaling pathway, which plays an important role in the development of many organisms (Ziemer et al., 2001; Taneyhill and Pennica, 2004) . These studies further indicate that KLF5 has a diverse role in different processes.
The KLF5 gene uses both its chromosomal copies to transcribe sufficient RNA, as deletion of one copy reduced its RNA expression level (Chen et al., 2002 (Chen et al., , 2003 Shindo et al., 2002) . Other factors also regulate the transcription of KLF5 (Chen et al., 2004) . Furthermore, KLF5 undergoes post-translational modifications including phosphorylation (Zhang and Teng, 2003) and acetylation (Miyamoto et al., 2003) . Tightly controlled protein regulation is a common feature to many transcription factors critically involved in cell growth control, such as p53 (Haupt et al., 1997) , HIF-1a (Huang et al., 1998) , c-myc (Salghetti et al., 1999) , and E2F (Campanero and Flemington, 1997) . In addition, instability of KLF5 protein has been suggested in two previous studies (Zhang and Teng, 2003; Bateman et al., 2004) . In this study, we tested if and how KLF5 protein is regulated in epithelial cells. We found that KLF5 protein undergoes rapid degradation, which is mediated at least in part by ubiquitination-proteasome pathway (UPP). A degradation signal of KLF5 appears to be located near a known transactivation domain (TAD) of KLF5. We also found that cancer cells are more active in degrading KLF5 protein.
Results

KLF5 protein degradation through proteasome
KLF5 protein was hardly detectable by Western blot in immortalized prostatic epithelial cell line PZ-HPV7, although this cell line expresses a high level of KLF5 RNA (Chen et al., 2003) . Proteasome inhibitor MG132 had been described to protect a KLF5 fusion protein in the HEC-1B human endometrial cancer cell line (Zhang and Teng, 2003) or KLF5 protein in intestinal epithelial cells (Bateman et al., 2004) . Therefore, we first tested the effect of MG132 treatment on the detection of KLF5 protein. As shown in Figure 1a , KLF5 protein is hardly detectable without MG132 treatment, but the level of KLF5 protein gradually increased with increasing concentrations of MG132 from 1 to 20 mM in PZ-HPV7 cells treated with MG132 for 4 h. MG132 at 20 mM or higher did not further increase the levels of KLF5 protein. When PZ-HPV7 cells were treated with 20 mM MG132 for different times, KLF5 protein levels gradually increased with the time of exposure from 0.5 to 4 h (Figure 1b ), but treatments longer than 4 h did not further increase KLF5 protein significantly.
To evaluate if proteasome pathway is responsible for KLF5's protein degradation, we treated PZ-HPV7 cells and the MCF10A immortalized breast epithelial cell line with inhibitors of different protein degradation pathways ( Figure 1c) . In both the cell lines, all proteasome inhibitors tested, including MG132, MG115, Epoxomicin, and PS341, significantly increased the level of KLF5 protein. However, KLF5 protein was still hardly detectable after treatment with leupeptin, an inhibitor for trypsin-like proteases and cysteine proteases, or the lysosome inhibitor ammonia chloride. We noticed that one or more protein bands of smaller molecular weights also appeared in both cell lines after the treatments with proteasome inhibitors. The molecular weight of one major band was about 37 kDa.
In live MCF10A epithelial cells, immunofluorescence staining showed that KLF5 protein was located in the nucleus of cells, and the treatment of MG132 significantly 
KLF5 protein is ubiquitinated
Ubiquitination is a common mechanism for protein degradation. To examine if KLF5 protein was ubiquitinated, we transfected a hemagglutinin (HA) epitopetagged ubiquitin (HA-Ub) expression plasmid into the RK2 prostate cancer cell line. This cell line was derived from the 22Rv1 prostate cancer cell line in which KLF5 with an N-terminal FLAG tag was stably expressed. Western blot analysis with an anti-HA antibody detected not only the HA-tagged ubiquitin (B10 kDa) but also a ladder of HA-ubiquitin-modified proteins (Figure 2a ). Upon the treatment of MG132, there was an increase in signal intensities for HA-Ub-modified total proteins. To determine if KLF5 is among the ubiquitinmodified proteins, we immunoprecipitated FLAG-KLF5 from RK2 cells transfected with HA-Ub using an anti-FLAG antibody and subjected the precipitated proteins to Western blot analysis with anti-HA antibody. As shown in Figure 2b , a ladder of HA-Ubmodified FLAG-KLF5 proteins was clearly detected. According to the molecular weights of FLAG-KLF5 and HA-Ub, the five visible bands in lane 2 corresponded to FLAG-KLF5 protein attached with one to five ubiquitin molecules. After the treatment with MG132 (lane 4), signal intensities for ubiquitinated FLAG-KLF5 protein increased, especially for those with more than five ubiquitin chains (Figure 2b) . Therefore, more extensive ubiquitination might lead to more rapid degradation of FLAG-KLF5.
To evaluate endogenous ubiquitination of KLF5 without HA-Ub expression, we immunoprecipitated FLAG-KLF5 with anti-FLAG antibody and tested the presence of ubiquitinated KLF5 with anti-Ub antibody. A smear of polyubiquitinated FLAG-KLF5 proteins was clearly detected in RK2 cells treated with MG132 ( Figure 2c ). However, ubiquitination of endogenous KLF5 protein was not detectable, which could be due to a lower efficiency of immunoprecipitation by anti-KLF5 and anti-Ub antibodies (data not shown).
We also transiently transfected 22Rv1 cells with FLAG-tagged KLF5 and HA-Ub, and performed immunoprecipitation under denaturing conditions that would dissociate any proteins interacting with ubiquitinated KLF5. As shown in Figure 3a , ubiquitination of KLF5 was clearly detected again, confirming that KLF5 itself is ubiquitinated.
Overlap of a transcription activation domain with KLF5 degron
For some important transcription factors such as c-myc, p53, and E2F-1, their TADs overlap with their degrons in directing their degradation (Salghetti et al., 2000) . For KLF5, a TAD (239-372) has been identified previously, and it appears to be associated with the stability of a fusion protein (Zhang and Teng, 2003) . The same TAD was suggested to reside within 15 amino acids (AA; 323-338) in another study (Kojima et al., 1997) . To explore the role of this TAD and its neighboring residues in ubiquitination and degradation of KLF5, we made two deletion constructions in which codons 323-348 (D1) and codons 293-348 (D2) of KLF5 were deleted, respectively, both spanning the 15 AA of the TAD. We then cotransfected HA-Ub plasmid with full-length KLF5 or deletion constructs, all with FLAG tag attached to their C-terminus, and performed immunoprecipitation combined with Western blotting with different antibodies. Following immunoprecipitation with anti-FLAG antibody combined with immunoblotting with anti-HA and anti-KLF5 antibodies, HA-Ub-modified total proteins and KLF5 protein were detected in cells transfected with different KLF5 constructs but not in the vector control. With or without the treatment of MG132, the amount of polyubiquitin-modified KLF5-FLAG decreased in the two deletion constructs ( Figure 3a , lanes 5-8) when compared to wild-type KLF5-FLAG (lane 3-4), and the reduction was more obvious in D2 than in D1. The reduction for D1 and D2 was not due to unequal loading of samples into the gel, as the amount of nonubiquitinated KLF5 was similar for wild-type and mutant KLF5 (Figure 3a , lower panel). These results indicate that deletion of amino acids spanning the TAD of KLF5 decreased KLF5's ubiquitination.
To evaluate if reduced ubiquitination was related to KLF5's stability, we measured the half-life of wild-type KLF5 and the two deletion mutants using the cycloheximide (CHX) chase and pulse chase. As shown in Figure 3b , degradation of wild-type KLF5 was visible at each time point. As a negative control, b-actin did not show degradation within the same time frame. A FLAG tag at C-terminus did not affect degradation of KLF5 (data not shown). We compared the half-lives of KLF5 and two deletion constructs D1 and D2 by CHX chase. The degradation rate of D1 is similar to KLF5-FLAG (Figure 3b ), but the degradation rate of D2 was significantly delayed. We confirmed this result by pulse chase experiments. As shown in Figure 3c , both wildtype KLF5 and D1 showed similar rate of degradation, whereas D2 showed a significantly longer half-life. As estimated by measuring band intensities, the half-life was 2 h for KLF5 without deletions but 6 h for KLF5 protein with 56-AA deletion (D2). Therefore, deletion of amino acids adjacent to the TAD (56-AA, 293-348) made KLF5 protein more stable.
Polypeptide enriched in proline (P), glutamate (E), serine (S), and threonine (T), known as the PEST sequence, can serve as a proteolysis signal (Rechsteiner and Rogers, 1996) . We analysed KLF5 protein by the PESTfind computer program (http://www.at.embnet.org/embnet/tools/bio/PESTfind/), and found two significant PEST motifs within KLF5. Although the PEST motif with the highest score (5.51) was located between codons 171 and 196, the sequence deleted in D2 (293-348) contained another PEST motif between 276 and 314 that has the second highest score (2.68).
Hyperactive degradation of KLF5 in cancer cells
To determine if KLF5 degradation differs between nonneoplastic and cancer cells, we measured KLF5 protein levels in a panel of breast cancer cell lines in which KLF5 mRNA levels were comparable to those in nonneoplastic cell lines and normal tissues (Figure 4a ). Upon the treatment of MG132 at 20 mM for 4 h, a higher level of KLF5 protein was detected in each of the four immortalized non-neoplastic breast epithelial cell lines (Figure 4a ). In 10 breast cancer cell lines, however, KLF5 protein was abundant only in the SW527 line, and was almost undetectable in the remaining nine cell lines under the same condition (Figure 4a ). Furthermore, when cells were treated with an increased concentration of MG132 (60 mM), the level of KLF5 protein did not further increase in each of the nonneoplastic breast cell lines but increased significantly in two breast cancer cell lines when compared to the treatment of 20 mM (Figure 4c ). Similar results were obtained in prostate cancer cell lines. As shown in Figure 4b , three immortalized non-neoplastic prostate epithelial cell lines PZ-HPV7, RWPE-1, and PWR1E showed a high level of KLF5 protein, but the PC-3 and MDAPCa2b prostate cancer cell lines showed significantly less KLF5 protein under the same condition (20 mM MG132), even though their RNA expression levels were comparable. The 22Rv1 prostate cancer cell line showed a similar low level of KLF5 protein, but its KLF5 RNA expression level is significantly lower than that in the PC-3 and MDAPCa2b cancer cell lines (Figure 4b ). When the concentration of MG132 was increased from 20 to 60 mM, the level of KLF5 protein did not further increase in the PZ-HPV7 non-neoplastic cell line but increased (Figure 4d ). Therefore, degradation of KLF5 appears to be more active in cancer cells than in non-neoplastic cells.
To evaluate if the difference in KLF5 protein accumulation between cancer cells and untransformed cells is due to a difference in their response to MG132, we examined MKP1 expression at both RNA and protein levels in the same prostate cell lines where KLF5 was examined. It has been reported that unphosphorylated MKP1 is also degraded through the UPP (Brondello et al., 1999) . As shown in Figure 4b and d, all but PC-3 of the six cell lines expressed MKP1 at similar RNA levels. Unlike KLF5, however, the pattern of MKP1 protein expression was not different between cancer and untransformed cell lines (Figure 4b) , and the rate of MKP1 accumulation upon MG132 treatment was not lower in PC-3 cells than in PWR-1E cells (Figure 4d ), which is different from KLF5. Therefore, it is less likely that less accumulation of KLF5 protein upon MG132 treatment in cancer cells is due to a weaker response to MG132.
To test if more rapid degradation of KLF5 protein is due to increased total proteasome activities in cancer cells, we examined their 20S proteasome activity by fluorogenic assay. No difference was found in proteasome activities between cancer cell lines and untransformed epithelial cell lines from both the breast and the prostate. This result suggests that hyperactive degradation of KLF5 in cancer cells is not due to nonspecific higher proteasome activity.
Discussion
KLF5 is an essential transcription factor that has important functions in multiple biological processes. In mice, complete knockout of KLF5 is lethal to embryogenesis, and partial deletion of KLF5 induced cardiovascular defects (Shindo et al., 2002) . KLF5 has also KLF5 degradation through ubiquitin-proteasome pathway C Chen et al been implicated in carcinogenesis as either a growth stimulator in untransformed cells or growth inhibitor in cancer cells (Sun et al., 2001; Chen et al., 2002 Chen et al., , 2003 Bateman et al., 2004) . In various human tumors, KLF5 undergoes frequent hemizygous deletion that leads to reduced expression of KLF5 mRNA (Knuutila et al., 1999; Chen et al., 2002 Chen et al., , 2003 , and the KLF5 gene is indeed haploinsufficient (Shindo et al., 2002) . Therefore, KLF5 is an essential molecule whose function is dose-dependent. In this study, we provide another mechanism, that is, ubiquitin-mediated proteolysis, for the regulation of KLF5 doses in epithelial cells, and show that this mechanism appears to be hyperactive in cancer cells.
We found that a proteasome-specific inhibitor, MG132, increased KLF5 protein levels in prostate epithelial cells in a dose-and time-dependent manner. Furthermore, additional proteasome inhibitors including MG115, Epoxomicin, and PS341 also stabilized KLF5 protein, but leupeptin, an inhibitor for trypsinlike proteases and cysteine proteases, and the lysosome inhibitor ammonia chloride could not protect KLF5 protein from degradation in prostate and breast epithelial cells. These data suggest that KLF5 is regulated by degradation through the proteasome pathway.
Proteins degraded through proteasome pathway are often first tagged by a polyubiquitin chain, which is mediated by three enzymes: E1 ubiquitin-activating enzyme, E2 ubiquitin-conjugating enzyme, and E3 ubiquitin ligase (Pickart, 2001) . E1 binds to and activates ubiquitin in an ATP-dependent manner and then passes ubiquitin to E2, which then transfers ubiquitin to a substrate through E3, a scaffold protein that recognizes specific substrate. Covalently polyubiquitinated proteins are rapidly detected and degraded by the proteasome. Using cells transfected with FLAGtagged KLF5 and HA-tagged ubiquitin genes, we detected a ladder of ubiquitinated KLF5 proteins (Figure 2b ). Endogenous ubiquitinated FLAG-KLF5 proteins were also detected without expressing HA-Ub (Figure 2c) . Furthermore, polyubiquitin-modified KLF5 protein was also detected under denaturing conditions (Figure 3a) , and MG132 treatment significantly enriched ubiquitinated KLF5 proteins (Figures 2b, c and 3a) . These data indicate that ubiquitination of KLF5 occurs in epithelial cells, which most likely leads to its degradation through the proteasome pathway.
It has been well documented that degrons of some important transcription factors frequently overlap with their TADs (Salghetti et al., 2000) . In a recent study, a TAD of KLF5 was identified and found to cause instability of a fusion protein between KLF5 TAD and GAL4 DNA binding domain (Zhang and Teng, 2003) . The minimal TAD promoting protein degradation was between codons 239 and 372 in KLF5. Consistent with this finding, our experiments clearly showed that deletion of 56 AA (293-348) including the TAD prevented the degradation of KLF5 (Figure 3 ). In addition, deletion of the same residues also decreased the level of ubiquitination for KLF5 (Figure 3 ). In the same study by Zhang and Teng (2003) , a minor TAD was also identified, but it did not cause instability of the fusion protein, suggesting that the major TAD plays a more important role in KLF5 transcription activation and stability. We therefore conclude that a degron of KLF5 overlaps with its major TAD, and this degron is involved in KLF5's ubiquitination during its degradation by proteasome pathway. We noticed that a smaller deletion (25-AA) that contains the defined 15-AA TAD (Kojima et al., 1997) slightly reduced ubiquitination but did not significantly stabilize KLF5 protein (Figure 3) . The overlap between TAD and degron sequence could be due to the common acidic activation domain (Herbst et al., 2004) .
We noticed that there were several smaller KLF5 protein bands after the treatment with proteasome inhibitors. The molecular weight of the major band was around 37 kDa. Another band is immediately below the wild-type KLF5 (Figure 1c ). In fact, existence of a lower molecular weight band of KLF5 protein has been observed by two independent groups (Shi et al., 1999; Bateman et al., 2004) . At present, how the smaller KLF5 proteins are generated is still unknown. These smaller KLF5 fragments are less likely from splicing variation of KLF5 RNA, as only one unique KLF5 mRNA species was detected in our previous Northern blot experiments (Chen et al., 2002 (Chen et al., , 2003 . It is more likely that these smaller KLF5 fragments result from the cleavage of wild-type KLF5 protein by another mechanism. We are currently testing this hypothesis.
Role of KLF5 as a tumor suppressor has been suggested by frequent genomic deletions and loss of expression as well as functional suppression of cancer cell growth (Chen et al., 2002 (Chen et al., , 2003 Bateman et al., 2004) . Hemizygous deletion leads to loss of expression of KLF5 (Chen et al., 2002 (Chen et al., , 2003 , and haploinsufficiency of KLF5 has been shown in a knockout study (Shindo et al., 2002) . Post-translational modifications including phosphorylation and acetylation also occur in KLF5 (Miyamoto et al., 2003; Zhang and Teng, 2003) . In the current study, we found that KLF5's protein level correlated with its RNA level in non-neoplastic epithelial cells upon the treatment of MG132, but in the majority of cancer cell lines that still express a higher level of KLF5 mRNA, KLF5 protein was not detectable with the same MG132 treatment or required a much higher concentration of MG132 to be detectable. We also demonstrated that the difference in MG132-induced KLF5 accumulation between cancer cells and untransformed epithelial cells was not due to different responses of cells to MG132, because MKP1, another protein that is also degraded by UPP, did not show different responses to MG132 in the same set of cells. This conclusion is supported by a recent study in which cancer cells appeared to be more sensitive than untransformed cells to MG132 treatment for KLF5 stabilization (Bateman et al., 2004) . Furthermore, the total proteasome activity was not higher in cancer cells when compared to untransformed cells. In a recent study (Bateman et al., 2004) , the ras oncoprotein downregulated KLF5 protein in intestinal cells and such an effect could be blocked by the MG132 proteasome inhibitor. It is thus likely that ras-induced KLF5 degradation is mediated by its upregulation of an E3 ligase for KLF5. Therefore, hyperdegradation of KLF5 protein in cancer cells is likely due to a specific mechanism such as a hyperactive E3 ligase for KLF5 in cancer cells. These findings not only present another mechanism of KLF5 regulation -ubiquitinationmediated proteasome degradation -but also suggest that increased KLF5 proteolysis is another mechanism to inactivate KLF5 function in carcinogenesis. Protein degradation through UPP is a common feature of many growth-related proteins such as p53 (Haupt et al., 1997) , IkBa (Chen et al., 1995) , and p27 (Loda et al., 1997) . Alteration in the degradation of these proteins is involved in carcinogenesis. Although the precise role of KLF5 in carcinogenesis remains to be clarified, its rapid turnover through UPP suggests its importance to cellular processes such as carcinogenesis, cell proliferation and differentiation, angiogenesis, and development.
KLF5 transcription factor belongs to the Kruppellike factor (KLF) family, which is structurally characterized by three zinc-finger domains at the C-terminus. Several members of KLF family, that is, Sp1 (Su et al., 1999; Grinstein et al., 2002) , KLF2/LKLF (Zhang and Teng, 2003; Zhang et al., 2004) , and TIEG1 (Johnsen et al., 2002) have also been demonstrated to be degraded through the UPP. In this study, we demonstrated UPP degradation of the KLF5 transcription factor. Tight regulation of these KLFs by UPP suggests that these molecules play important roles in different physiological and pathological processes. Indeed, expression of KLFs is tissue specific, and they appear to be involved in cellular proliferation, differentiation, cell cycle progression, apoptosis, angiogenesis, and development (Dang et al., 2000; Black et al., 2001) . It is thus possible that more members of the KLF family are degraded through UPP.
In summary, we demonstrated that KLF5 protein is highly unstable in epithelial cells, and its degradation is most likely mediated through the UPP. A 56-AA sequence overlapping with a TAD of KLF5 is involved in KLF5's ubiquitination and degradation. Finally, degradation of KLF5 is more active in both breast and prostate cancer cells.
Materials and methods
Cell culture and treatment
Most cell lines used in this study have been described previously (Chen et al., 2002 (Chen et al., , 2003 . The 22Rv1 prostate cancer cell line was maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), HEPES (0.1 M), sodium pyruvate (1 mM), sodium bicarbonate (0.15%), glucose (0.45%), and penicillin and streptomycin. Prostate cancer cell line MDAPCa2b and immortalized but untransformed breast epithelial cell lines MCF10A, 184A1, and 184B5 were purchased from the American Type Culture Collection (ATCC) (Manassas, VA, USA) and were propagated according to conditions recommended by ATCC. FLAG-KLF5-expressing RK2 cell line was derived from the 22Rv1 prostate cancer cell line. Briefly, KLF5 coding region was amplified from pcDNA3-KLF5 (Chen et al., 2002) by PCR with primers containing enzyme sites for BsiWI and XhoI, and cloned into the pKXU retrovirus vector (Murphy et al., 2002) between the same two restriction enzyme sites. Recombinant retrovirus was prepared and used to infect 22Rv1 cells according to established protocols (Murphy et al., 2002) . Stable clones were established following the infection, and expression of KLF5 in these clones was verified by Northern blot analysis.
Proteasome inhibitors MG132 and MG115 were purchased from Sigma. Trypsin-like protease and cysteine protease inhibitor leupeptin and proteasome inhibitor Epoxomicin were from EMD Biosciences (La Jolla, CA, USA). These reagents were dissolved and used according to the manufacturer's procedures.
Plasmid constructions and transient transfection
For the construction of pcDNA3-KLF5-FLAG, we used the pcDNA3-KLF5 plasmid (Chen et al., 2002) , which has one methylation-sensitive XbaI site in the middle of KLF5 and one methylation-insensitive XbaI site at the 3 0 -end of KLF5. The pcDNA3-KLF5 plasmid was prepared from Escherichia coli SCS110 (damÀ), which made the XbaI site in the middle of KLF5 accessible. This plasmid was digested with XbaI to prepare the cloning vector. For the insert preparation, PCR products using forward primer 5 0 -GATCTAGATATGCCC AGTTC-3 0 (XbaI site attached) and reverse primer 5 0 -TTTCT AGACTACTTGTCATCGTCGTCCTTGTAATCGTTCTGG TGCCTCTTCATAT-3 0 (XbaI site and FLAG tag attached) were digested with XbaI and cloned into the above prepared vector to generate pcDNA3-KLF5-FLAG.
Two plasmids with deletions, that is, pcDNA3-KLF5D1-FLAG (codons 323-348 deleted) and pcDNA3-KLF5D2-FLAG (codons 293-348 deleted), were constructed from pcDNA3-KLF5-FLAG using PCR-based approaches. Briefly, PCR products were generated with the same forward primer described above (XbaI site attached) and either reverse primer 5 0 -TTGTTAACGGTTAAATTCTGGAGCATCT-3 0 (HpaI site attached) or 5 0 -TTGTTAACAAACTGACTTGG CATTGTGT-3 0 (HpaI site attached). These PCR products were digested with XbaI and HpaI to prepare the insert. In the preparation of cloning vector, pcDNA3-KLF5-FLAG plasmid was isolated from E. coli DH5a (dam þ ) to protect the XbaI site in the middle of KLF5, digested with XbaI, end-filled with Klenow enzyme to inactivate the XbaI site at the end of KLF5 gene, self-ligated, and transformed into E. coli SCS110 (damÀ) to generate a modified pcDNA3-KLF5-FLAG plasmid, which was digested with XbaI and HpaI to clone the DNA fragments with deletions from above.
KLF5 antibody preparation
A DNA fragment encoding codons 88-374 of KLF5 was amplified with PCR using primers 5 0 -TTGGATCCACAA GATGTGAAATGGAGAAGT-3 0 (BamHI site attached) and 5 0 -TTGAATTCTCAGTAGTGGATGCGTCGTTT-3 0 (EcoRI site attached) and cloned into the pGEX-2TK glutathione S-transferase (GST) fusion protein expression vector (Amersham Biosciences, Piscataway, NJ, USA). The construct was transformed into E. coli strain BL21 (DE3) (Stratagene, CA, USA) and the fusion protein GST-KLF5D was induced by IPTG. The fusion protein was purified with glutathione sepharose 4B column and MonoQ anion exchange column. KLF5D protein was further purified through S-200 superdex size exclusion column after removing GST by thrombin.
KLF5 degradation through ubiquitin-proteasome pathway C Chen et al Purified protein was analysed by 10% SDS-PAGE and the purity was determined by Coomassie blue staining. Two New Zealand white rabbits were immunized with 0.1 mg KLF5D antigen per rabbit followed by three booster injections with 0.1 mg antigen at regular intervals. Serum at 10 weeks was collected and analysed by ELISA and Western blot analysis.
Immunofluorescence assay
MCF10A breast epithelial cells were seeded into 16-well chamber slides at a density of 1 Â 10 4 cells/well. After treatment with 10 mM MG132 for 8 h, cells were fixed with 4% paraformaldehyde in PBS for 20 min at room temperature. Slides were washed twice with PBS for 5 min each, incubated with Super-block (Scy Tek Logan, UT, USA) for 30 min, washed twice, incubated with 1 : 50 diluted KLF5 antibody or prebleed serum for 1 h in a humidified chamber at room temperature, washed three times, incubated with rhodamine (TRITC)-conjugated donkey anti-rabbit second antibody IgG (H þ L) (Jackson Immuno Research, PA, USA), washed three times, mounted, and examined under fluorescence microscope.
Western blot and immunoprecipitation
Cells were seeded at 1 Â 10 6 cells/60 mm or 3 Â 10 6 cells/100 mm dishes. Plasmids were transfected into cells using the lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA). At 48 h following transfection, cells were treated with 20 mM MG132 for 4 h if necessary, and harvested using RIPA buffer (1 Â PBS, 0.1% SDS, 1% Igepal CA-630, 0.5% sodium deoxycholate, 1% Sigma cocktail proteinase inhibitors I, 1 mM sodium orthovanadate, and 0.1 mg/ml PMSF) for Western blot analysis. Anti-FLAG monoclonal antibody (mAb), anti-atubulin mAb, and anti-actin rabbit polyclonal antibody were purchased from Sigma. Anti-HA rabbit polyclonal antibody and all second antibodies were from Cell Signaling. Anti-Ub mAb and anti-MKP1 antibody were from Santa Cruz.
For immunoprecipitation under denaturing conditions, cells from one 60 mm dish were resuspended in 0.2 ml of 0.5 mM Tris-HCl (pH 6.8)/1.5% SDS and boiled for 15 min. Samples were then diluted in 8 volumes of EBC/BSA buffer (50 mM Tris-HCl (pH 6.8), 180 mM NaCl, 0.5% CA630, and 0.5% BSA). In brief, 100 ml of 50% slurry of FLAG-M2 beads was added and the mixture was rotated overnight at 41C. The beads were washed three times by vortexing using EBC/BSA buffer followed by spinning for 5 s at 10 000 g. After wash, proteins were boiled in 2 Â SDS sample buffer (Bio-Rad) and examined by Western blotting. For immunoprecipitation under nondenaturing conditions, the procedures were the same as described above, except that the cells were collected and beads were washed with TBS buffer (150 mM NaCl, 50 mM Tris-HCl (pH 7.4), 1% Triton X-100, and 1% Sigma cocktail proteinase inhibitors I).
Protein half-life measurement CHX chase: Cells were seeded into 60 mm dishes at a density of 1 Â 10 6 cells/dish. After incubating overnight, cells were transfected with KLF5 constructs using lipofectamine 2000. At 24 h after transfection, cells were treated with 50 mg/ml CHX for varying lengths of time. Total proteins were collected and subjected to Western blot for KLF5 and b-actin. Pulse chase: Transfected cells were starved in DMEM medium (met/cysfree, supplemented with 5% dialysed FBS) for 30 min. A 30 ml portion of Tran 35 S-label (ICN, B10 mCi/ml) was added into each plate for 40 min. Cells were washed twice with PBS and incubated with full DMEM medium (supplemented with 5% FBS, 2 mM methionine, and 2 mM cysteine). At different chase times (1-3 h), cells were harvested into 0.2 ml lysis buffer (25 mM Tris-HCl (pH 6.8) and 1.5% SDS) by scraping and boiled for 15 min. Denaturing immunoprecipitation was performed as described above. SDS-PAGE gels were dried and exposed to X-ray film for autoradiography. Band intensities were measured using the IMAGE J program from NIH (http://rsb.info.nih.gov/ij) and plotted against the time of treatment.
RT-PCR
Total RNAs were isolated using TRIzol s reagent (Invitrogen). Reverse transcriptions were performed using the Iscript TM cDNA synthesis kit (Bio-Rad). Forward primer 5 0 -CTTCCAC AACAGGCCACTTAC-3 0 and reverse primer 5 0 -TCAGTT CTGGTGCCTCTTCA-3 0 were used to amplify KLF5 by PCR in a volume of 25 ml. Primer sequences for MKP1 were 5 0 -CCCGGAGCTGTGCAGCAA-3 0 (forward) and 5 0 -CTGG CCCATGAAGCTGAAGT-3 0 (reverse). A total of 32 cycles were used to amplify KLF5 and MKP1, whereas 28 cycles were used to amplify the b-actin control.
Measurement of 20S proteasome activity
20S proteasome activity is quantified by monitoring the release of AMC from the fluorogenic peptide Suc-Leu-Leu-Val-Tyr-AMC. Briefly, cells in 60-mm dishes were collected by using 0.5 ml lysis buffer (50 mM HEPES, pH 7.9, 5 mM EDTA, 150 mM NaCl, and 1% Triton X-100) and scraping. After incubating for 1 h on ice, cell lysate was centrifuged at 7000 g for 10 min. The supernatant was transferred and the protein concentration was measured with the Bio-Rad Dc kit. Protein (10 mg) was mixed with 100 ml fresh substrate buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, and 50 mM Ys substrate Succinyl-Leu-Val-Tyr-Amido-4-Methyl-Coumarin, pH 8.0) in a 96-well microplate. Following incubation for 1 h at 371C, the plate was read using fluorometer with 380 nM excitation and 460 nM emission filter set.
